VANCOUVER, British Columbia - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ('the 'Company') announces that further to its news release of October 29, 2020, the noninterest bearing convertible note in the principal amount of $85,000 which it issued in settlement of debt has been converted into 566,667 common shares of the Company at a deemed price of $0.15 per share.

Contact:

Investor and Public

Veritas Pharma Inc.

Telephone: +1.416.918.6785

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

(C) 2021 Electronic News Publishing, source ENP Newswire